HBOT for Crush Injury and Compartment Syndrome: An Underused FDA-Cleared Lifesaver

Emergency trauma bay with hyperbaric chamber visible through glass, medical staff attending to patient with crush injury

When a building collapses, a heavy object pins a limb, or a high-impact crush injury occurs, the clock starts ticking. Beyond the visible trauma, a silent killer often lurks: compartment syndrome, where pressure builds within muscle compartments, cutting off blood flow and threatening tissue survival. In these time-critical emergencies, hyperbaric oxygen therapy (HBOT) stands as one of the few FDA-cleared interventions that can mean the difference between limb salvage and amputation.

The Physiology of Crush Injury and Compartment Syndrome

Crush injuries occur when forceful compression damages muscle, nerves, and blood vessels. The damage extends beyond the initial impact. When pressure is released—during extrication or surgery—toxins flood the bloodstream, potentially causing crush syndrome with renal failure, cardiac arrhythmias, and death.

Compartment syndrome develops when swelling within a confined anatomical space raises pressure above perfusion pressure. Muscle and nerve tissue begin dying within 4–6 hours. The standard of care is emergency fasciotomy—surgical incision to release pressure. But even after fasciotomy, tissue at the margins may remain ischemic, creating a window where HBOT can preserve threatened tissue.

Why HBOT Works in Acute Traumatic Ischemia

Hyperbaric oxygen therapy delivers 100% oxygen at pressures typically 2.0–2.5 atmospheres absolute (ATA). This dramatically increases the amount of dissolved oxygen in plasma—enough to sustain cellular metabolism even without hemoglobin. For crush-injured tissue with compromised microcirculation, this oxygen bridge can keep cells alive until angiogenesis restores normal perfusion.

The mechanisms extend beyond oxygen delivery. HBOT:

Reduces edema by causing arteriolar vasoconstriction while maintaining oxygen delivery
Blunts reperfusion injury by scavenging free radicals and reducing neutrophil adhesion
Enhances antibiotic efficacy against anaerobic organisms like Clostridium perfringens
Promotes angiogenesis and collagen synthesis in marginal tissue

The FDA-Clearance Context

The FDA recognizes crush injury, compartment syndrome, and acute traumatic ischemias as cleared indications for HBOT. This places these conditions alongside decompression sickness, carbon monoxide poisoning, and gas gangrene as established uses—not experimental or off-label.

However, this clearance comes with important caveats. HBOT is adjunctive, not primary therapy. Emergency fasciotomy remains the gold standard for compartment syndrome. HBOT supplements surgical decompression, antibiotics, and supportive care. The FDA emphasizes that HBOT must be administered in accredited facilities with proper safety protocols—particularly relevant given the 2025–2026 safety warnings about hyperbaric chamber fires.

Evidence and Clinical Practice

Randomized controlled trials specifically for HBOT in crush injury are limited by the ethical challenges of withholding treatment in emergencies. Much of the evidence comes from case series, animal models, and physiological studies. A 2006 case series published in Archives of Medical Research documented successful HBOT use in bilateral compartment syndrome with rhabdomyolysis and acute renal failure following heroin intake, suggesting benefit even in complex, multi-system trauma.

The Undersea and Hyperbaric Medical Society (UHMS) guidelines recommend HBOT for crush injury and compartment syndrome when tissue viability is threatened despite surgical intervention. Typical protocols involve 2.0–2.5 ATA for 90 minutes, with daily sessions continuing until tissue perfusion stabilizes—often 5–10 treatments.

Timing: The Critical Window

In acute traumatic ischemia, time is tissue. Animal studies suggest HBOT is most effective when initiated within 6–24 hours of injury. Beyond this window, irreversible ischemic changes occur, and the benefit diminishes. This creates logistical challenges: not every hospital has hyperbaric capabilities, and transferring a critically injured patient requires careful risk-benefit analysis.

Some trauma centers are exploring in-hospital hyperbaric units or mobile chambers to reduce delays. The military has long recognized HBOT’s value in combat trauma, where crush injuries from blast and building collapse are common. Civilian trauma systems are increasingly integrating hyperbaric medicine into protocols for complex extremity injuries.

Safety in the Spotlight

The hyperbaric medicine community is currently grappling with safety concerns following two fatal chamber fires—one in Lake Havasu, Arizona in July 2025, and another in Troy, Michigan in January 2025 that claimed the life of a five-year-old child. These tragedies underscore that HBOT, while clinically valuable, carries risks when safety protocols are compromised.

For crush injury and compartment syndrome patients—often already hemodynamically unstable—chamber safety is paramount. Absolute contraindications include untreated pneumothorax and certain chemotherapy agents. Relative contraindications like claustrophobia or fever require careful management. The 2025 FDA safety letter specifically warned against improper home use of hyperbaric devices—a concern less relevant in acute trauma settings but critical for the broader HBOT landscape.

The Broader Context: HBOT in Emergency Medicine

Crush injury represents one of several FDA-cleared emergency indications for HBOT. Gas gangrene (clostridial myonecrosis), necrotizing fasciitis, and decompression sickness share the same physiological rationale: delivering oxygen to threatened tissue, inhibiting anaerobic infection, and supporting host defenses.

Yet awareness among emergency physicians varies. A 2024 survey suggested many emergency medicine residents receive minimal training in hyperbaric medicine indications. As trauma systems evolve, integrating HBOT into protocols for crush injury, necrotizing soft tissue infections, and acute carbon monoxide poisoning remains an ongoing challenge.

What Patients and Families Should Know

If you or a loved one suffers a crush injury with suspected compartment syndrome, understanding HBOT’s role can inform advocacy:

Ask about HBOT early. Once fasciotomy is performed, inquire whether hyperbaric consultation is appropriate for marginal tissue.
Verify facility accreditation. The UHMS accredits hyperbaric facilities; treatment in accredited centers ensures adherence to safety standards.
Understand the timeline. HBOT’s benefit diminishes with delay; push for timely evaluation if tissue viability is uncertain.
Recognize adjunctive status. HBOT supplements, never replaces, surgical decompression and standard trauma care.

Looking Forward

Research continues into optimizing HBOT protocols for acute traumatic ischemia. Questions include: What is the ideal pressure and duration? Can biomarkers identify patients most likely to benefit? How can telemedicine and mobile chambers extend access to rural trauma centers?

For now, crush injury and compartment syndrome remain firmly in HBOT’s FDA-cleared portfolio—a testament to decades of clinical experience and physiological rationale. In the race against time that follows traumatic limb injury, hyperbaric oxygen offers a proven, if underutilized, tool for tissue salvage.

HBOToday Editorial provides evidence-based reporting on hyperbaric oxygen therapy. This article is for informational purposes only and does not constitute medical advice. Always consult qualified healthcare providers for treatment decisions.

Sources

← Back to blog